Fingerprint
Dive into the research topics of 'Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically